# Climb Bio (CLYM) — News

CLYM · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/clym/news

## Recent headlines

- [Climb Bio added to Raymond James analyst favorites list](https://www.ainvest.com/news/climb-bio-added-raymond-james-analyst-favorites-list-2609) — AInvest Wire, Sep 23, 2026
- [Climb Bio, Inc.: Oppenheimer raises target price to $25 from $18](https://www.ainvest.com/news/climb-bio-oppenheimer-raises-target-price-25-18-2609) — AInvest Wire, Sep 8, 2026
  Climb Bio, Inc. (CLYM) has seen recent analyst activity with Oppenheimer raising its price target for the stock to $25 from $18, reflecting a positive outlook on the clinical-stage biotechnology company’s prospects. The updated target aligns with broader analyst sentiment, as multiple firms have…
- [Climb Bio, Inc.: H.C. Wainwright raises target price to $30 from $24](https://www.ainvest.com/news/climb-bio-wainwright-raises-target-price-30-24-2609) — AInvest Wire, Sep 8, 2026
  H.C. Wainwright & Co. has revised its price target for Climb Bio, Inc. (NASDAQ: CLMB), raising it to $30 from $24 , reflecting a positive reassessment of the company’s outlook. The adjustment follows recent developments in the company’s pipeline and ongoing clinical trials, which have drawn…
- [Climb Bio Inc shares jump 14% after phase 1 data update](https://www.ainvest.com/news/climb-bio-shares-jump-14-phase-1-data-update-2609) — AInvest Wire, Sep 3, 2026
- [Climb Bio's CLYM116 shows ~29-day half-life in phase 1](https://www.ainvest.com/news/climb-bio-clym116-shows-29-day-life-phase-1-2609) — AInvest Wire, Sep 3, 2026
  Climb Bio, Inc. (Nasdaq: CLYM) recently reported preliminary data from its Phase 1 clinical trial of CLYM116, a preclinical-stage monoclonal antibody targeting APRIL (A Proliferation-Inducing Ligand). The trial, conducted in normal healthy volunteers, demonstrated a half-life of approximately 29…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).